These companies have announced their intention to participate:

Boehringer Ingelheim (Jardiance for type 2 diabetes): Although Eli Lilly and Boehringer Ingelheim jointly developed Jardiance through an alliance that dates back to 2011, Lilly said Boehringer Ingelheim "has sole responsibility for pricing, reimbursement and access to Jardiance," and Lilly will not have any role in the price set by CMS. "We are committed to engaging in open and transparent conversations with CMS," the company told Endpoints News. "We look forward to sharing detailed information with CMS on the value of Jardiance and to reinforce the need to invest in scientific medical innovation for the patients we serve."
Bristol Myers Squibb (Eliquis, a blood thinner): "We have no choice other than to sign the 'agreement,'" the company said. "If we did not sign, we'd be required to pay impossibly high penalties unless we withdraw all of our medicines from Medicare and Medicaid. That is not a real choice."
AstraZeneca (Farxiga for type 2 diabetes): "We remain committed to ensuring patients have access to Farxiga and plan to participate in the process outlined by CMS to communicate the value of Farxiga to people covered by Medicare," the company said.
Merck (Januvia for type 2 diabetes): The drugmaker will sign the agreement to participate "under protest," noting that it disagrees on "both legal and policy grounds" with the negotiations. But "withdrawing all of the company's products from Medicare and Medicaid would have devastating consequences for the millions of Americans who rely on our innovative medicines, and it is not tenable for any manufacturer to abandon nearly half of the U.S. prescription drug market," a spokesperson said.

Related: First 10 drugs set for Medicare price negotiations: Will pharma participate?

The other manufacturers selected for the first round of negotiations – Amgen, Johnson & Johnson, Novartis and Novo Nordisk – have not yet announced their intentions regarding the deadlines.

Instant Insights /

Drugmakers reluctantly agree to Medicare drug price negotiations, as lawsuits continue

More From HR Executive

Related Stories

Recommended For You